
Linzagolix

产品编号: D52470

CAS: 935283-04-8

分子式: C₂₂H₁₅F₃N₂O₇S

纯度: 99.68%

InChi Key: InChiKey=BMAAMIIYNNPHAB-UHFFFAOYSA-N

Smiles: COc(c(COc(c(OC)c1)cc(N(C(c2c(C(O)=O)scc2N2)=O)C2=O)c1F)c1F)ccc1F

外观: 固体粉末

作用通路: GPCR/G Protein

作用靶点: GNRH Receptor

溶解性: DMSO: 55 mg/ml (108.18 mM)

保存条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

产品介绍: Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.